Read by QxMD icon Read

Ki67 breast cancer

Patrizia Ferroni, Francesca Santilli, Francesco Cavaliere, Paola Simeone, Leopoldo Costarelli, Rossella Liani, Romina Tripaldi, Silvia Riondino, Mario Roselli, Giovanni Davi, Fiorella Guadagni
The hypothesis that increased oxidative stress in breast cancer (BC) patients could induce enhanced lipid peroxidation, which, in turn, would contribute to platelet activation and poor clinical outcome is attractive. To address this issue, we investigated pre-surgical urinary 8-iso-prostaglandin (PG)F2α (marker of in vivo oxidative stress) and 11-dehydro-thromboxane (TX)B2 (marker of in vivo platelet activation) levels in patients with primary BC (n=115) compared with control women paired for co-morbidities and their association with patients' metabolic profile and clinical prognostic factors...
October 26, 2016: International Journal of Cancer. Journal International du Cancer
Ruohong Shui, Baohua Yu, Rui Bi, Fei Yang, Wentao Yang
No abstract text is available yet for this article.
February 2016: Pathology
Ingunn Holen, Diane V Lefley, Sheila E Francis, Sarah Rennicks, Steven Bradbury, Robert E Coleman, Penelope Ottewell
BACKGROUND: We have recently identified interleukin 1B (IL-1B) as a potential biomarker for predicting breast cancer patients at increased risk for developing bone metastasis. In mouse models, IL-1B and its receptor (IL-1R1) are upregulated in breast cancer cells that metastasise to bone compared with cells that do not. We have now investigated the functional role of IL-1 by blocking IL-1R signalling with the clinically licensed antagonist, anakinra. METHODOLOGY: 6-week old female BALB/c mice received a subcutaneous or intra-venous injection of MDA-MB-231-IV or MCF7 cells...
September 27, 2016: Oncotarget
Mustapha Abubakar, Nick Orr, Frances Daley, Penny Coulson, H Raza Ali, Fiona Blows, Javier Benitez, Roger Milne, Herman Brenner, Christa Stegmaier, Arto Mannermaa, Jenny Chang-Claude, Anja Rudolph, Peter Sinn, Fergus J Couch, Peter Devilee, Rob A E M Tollenaar, Caroline Seynaeve, Jonine Figueroa, Mark E Sherman, Jolanta Lissowska, Stephen Hewitt, Diana Eccles, Maartje J Hooning, Antoinette Hollestelle, John W M Martens, Carolien H M van Deurzen, kConFab Investigators, Manjeet K Bolla, Qin Wang, Michael Jones, Minouk Schoemaker, Jelle Wesseling, Flora E van Leeuwen, Laura Van 't Veer, Douglas Easton, Anthony J Swerdlow, Mitch Dowsett, Paul D Pharoah, Marjanka K Schmidt, Montserrat Garcia-Closas
BACKGROUND: The value of KI67 in breast cancer prognostication has been questioned due to concerns on the analytical validity of visual KI67 assessment and methodological limitations of published studies. Here, we investigate the prognostic value of automated KI67 scoring in a large, multicentre study, and compare this with pathologists' visual scores available in a subset of patients. METHODS: We utilised 143 tissue microarrays containing 15,313 tumour tissue cores from 8088 breast cancer patients in 10 collaborating studies...
October 18, 2016: Breast Cancer Research: BCR
Xiaolan Feng, Haocheng Li, Elizabeth N Kornaga, Michelle Dean, Susan P Lees-Miller, Karl Riabowol, Anthony M Magliocco, Don Morris, Peter H Watson, Emeka K Enwere, Gwyn Bebb, Alexander Paterson
INTRODUCTION: This study was designed to investigate the combined influence of ATM and Ki67 on clinical outcome in early stage hormone receptor positive breast cancer (ES-HPBC), particularly in patients with smaller tumors (< 4 cm) and fewer than four positive lymph nodes. METHODS: 532 formalin-fixed paraffin-embedded specimens of resected primary breast tumors were used to construct a tissue microarray. Samples from 297 patients were suitable for final statistical analysis...
October 12, 2016: Oncotarget
J Li, Z J Song, Y Y Wang, Y Yin, Y Liu, X Nan
MicroRNA (miRNA) deregulation has been previously linked to the initiation and development of breast cancer. Although miR-99a is aberrantly expressed in many types of cancers, including breast cancer, the serum miR-99a expression level in breast cancer and its clinical significance remains unknown. Blood samples were obtained from 72 patients with breast cancer and 40 healthy volunteers, and subjected to real-time polymerase chain reaction to evaluate the level of expression of serum miR-99a in the study participants...
August 26, 2016: Genetics and Molecular Research: GMR
Esther Carrasco, Jose Manuel Garrido, Pablo Juan Álvarez, Enrique Álvarez-Manzaneda, Rachid Chahboun, Ibtissam Messouri, Consolación Melguizo, Antonia Aránega, Fernando Rodríguez-Serrano
INTRODUCTION: Recently, we have reported the antitumor properties of a new family of synthetic merosesquiterpenes, among which meroxest is highlighted, since it has high activity and specificity for ER(+) breast cancer cells. In this paper, we characterize allografts of ER(+) E0771 mouse breast tumor cells in immunocompetent C57BL/6 mice, and also analyze the effect of meroxest on the prognosis of the disease. MATERIAL AND METHODS: Twenty female C57BL/6 mice were injected with 10(6) E0771 cells...
October 1, 2016: Archives of Medical Science: AMS
Flora Stavridi, Konstantine T Kalogeras, Kyriaki Pliarchopoulou, Ralph M Wirtz, Zoi Alexopoulou, Flora Zagouri, Elke Veltrup, Eleni Timotheadou, Helen Gogas, Angelos Koutras, Georgios Lazaridis, Christos Christodoulou, George Pentheroudakis, Apostolos Laskarakis, Petroula Arapantoni-Dadioti, Anna Batistatou, Maria Sotiropoulou, Gerasimos Aravantinos, Pavlos Papakostas, Paris Kosmidis, Dimitrios Pectasides, George Fountzilas
BACKGROUND-AIM: Early breast cancer is a heterogeneous disease, and, therefore, prognostic tools have been developed to evaluate the risk for distant recurrence. In the present study, we sought to develop a risk for recurrence score (RRS) based on mRNA expression of three proliferation markers in high-risk early breast cancer patients and evaluate its ability to predict risk for relapse and death. In addition the Adjuvant! Online score (AOS) was also determined for each patient, providing a 10-year estimate of relapse and mortality risk...
2016: PloS One
Bo Pan, Ru Yao, Qing-Li Zhu, Chang-Jun Wang, Shan-Shan You, Jing Zhang, Qian-Qian Xu, Feng Cai, Jie Shi, Yi-Dong Zhou, Feng Mao, Yan Lin, Jing-Hong Guan, Song-Jie Shen, Zhi-Yong Liang, Yu-Xin Jiang, Qiang Sun
PURPOSE: The mainstay modality of breast cancer screening in China is the hospital-based opportunistic screening among asymptomatic self-referred women. There is little data about the ultrasound (US) detected non-palpable breast cancer (NPBC) in Chinese population. METHODS: We analyzed 699 consecutive NPBC from 1.8-2.3 million asymptomatic women from 2001 to 2014, including 572 US-detected NPBC from 3,786 US-positive women and 127 mammography (MG) detected NPBC from 788 MG-positive women...
September 28, 2016: Oncotarget
Ryutaro Mori, Manabu Futamura, Kasumi Morimitsu, Kazuhiro Yoshida
The appropriate therapy for metastatic breast cancer must be selected based on the immunohistochemical phenotype of the cancer. However, biopsy for metastatic lesions is difficult. We herein report a patient with incidental appendicitis caused by a metastatic breast cancer which was successfully treated with effective therapy chosen based on the pathological diagnosis obtained on resection. The patient was a 56-year-old female with right breast cancer and an immunohistochemical status of estrogen receptor (ER) (+), progesterone receptor (PgR) (+), human epidermal growth factor receptor 2 (HER2) (3+), and Ki67 40 %...
December 2016: Surgical Case Reports
Andriy Marusyk, Doris Tabassum, Michalina Janiszewska, Andrew Place, Anne Trinh, Andrii I Rozhok, Saumyadipta Pyne, Jennifer Guerriero, Shaokun Shu, Muhammad Ekram, Alexander Ishkin, Daniel P Cahill, Yuri Nikolsky, Timothy A Chan, Mothaffar F Rimawi, Susan G Hilsenbeck, Rachel Schiff, C Kent Osborne, Anthony Letai, Kornelia Polyak
Using a 3D co-culture model, we identified significant sub-type-specific changes in gene expression, metabolic, and therapeutic sensitivity profiles of breast cancer cells in contact with cancer-associated fibroblasts (CAFs). CAF-induced gene expression signatures predicted clinical outcome and immune-related differences in the microenvironment. We found that fibroblasts strongly protect carcinoma cells from lapatinib, attributable to its reduced accumulation in carcinoma cells and an elevated apoptotic threshold...
September 26, 2016: Cancer Research
Hiroaki Aoki, Masayo Aoki, Eriko Katsuta, Rajesh Ramanathan, Michael O Idowu, Sarah Spiegel, Kazuaki Takabe
BACKGROUND: There are no effective treatments for pancreatic cancer peritoneal carcinomatosis (PC) or cancer dissemination in abdominal cavity. Sphingosine-1-phosphate (S1P), a bioactive lipid mediator produced by sphingosine kinases (SphK1 and SphK2), plays critical roles in cancer progression. We reported that SphK1, but not SphK2, is responsible for S1P export from breast cancer cells and recently discovered that S1P is linked to inflammation and cancer in colitis-associated cancer progression...
October 2016: Journal of Surgical Research
Sirwan M Hadad, Lee B Jordan, Pankaj G Roy, Colin A Purdie, Takayuki Iwamoto, Lajos Pusztai, Stacy L Moulder-Thompson, Alastair M Thompson
BACKGROUND: Sequential biopsy of breast cancer is used to assess biomarker effects and drug efficacy. The preoperative "window of opportunity" setting is advantageous to test biomarker changes in response to therapeutic agents in previously untreated primary cancers. This study tested the consistency over time of paired, sequential biomarker measurements on primary, operable breast cancer in the absence of drug therapy. METHODS: Immunohistochemistry was performed for ER, PR and Ki67 on paired preoperative/operative tumor samples taken from untreated patients within 2 weeks of each other...
September 22, 2016: BMC Cancer
Miyuki Kanematsu, Masami Morimoto, Masako Takahashi, Junko Honda, Yoshimi Bando, Takuya Moriya, Yukiko Tadokoro, Misako Nakagawa, Hirokazu Takechi, Takahiro Yoshida, Hiroaki Toba, Mitsuteru Yoshida, Aiichiro Kajikawa, Akira Tangoku, Issei Imoto, Mitsunori Sasa
Background Overdiagnosis in mammography (MMG) is a problem. Combination of MMG and ultrasonography for breast cancer screening may increase overdiagnosis. Most cases of overdiagnosis are low-grade ductal carcinoma in situ (LGD), but no reports have focused on them. Materials and methods We immunostained 169 ductal carcinoma in situ (DCIS) cases for ER, PgR, HER2 and Ki67 and classified them into 4 subtypes: ER(+)/HER2(-), ER(+)/HER2(+), ER(-)/HER2(-) and ER(-)/HER2(+). The Ki67 index was used to evaluate the grade of malignancy and examined for correlations with each ER/HER2 subtype and the nuclear grade (NG), with/without comedo necrosis...
2016: Journal of Medical Investigation: JMI
U Nitz, O Gluz, J Huober, H H Kreipe, R E Kates, A Hartmann, R Erber, Z Moustafa, M Scholz, B Lisboa, S Mohrmann, V Möbus, D Augustin, G Hoffmann, E Weiss, S Böhmer, R Kreienberg, A Du Bois, D Sattler, C Thomssen, M Kiechle, F Jänicke, D Wallwiener, N Harbeck, W Kuhn
No abstract text is available yet for this article.
September 15, 2016: Annals of Oncology: Official Journal of the European Society for Medical Oncology
Hee Young Na, Ji-Young Choe, Seon Ah Shin, Ho-Kyung Choung, Sohee Oh, Jin-Haeng Chung, Mira Park, Ji Eun Kim
Despite recent progress in comprehensive genetic analysis, little is known about the molecular pathogenesis of sebaceous carcinoma. On the basis of the ontogenic proximity of sebaceous and mammary glands, we designed an intrinsic classification for sebaceous carcinoma adapted from that of breast cancer and evaluated its clinical significance. We investigated 42 cases of sebaceous carcinoma, including 32 ocular and 10 extraocular cases. Immunohistochemical analyses for estrogen receptor (ER), progesterone receptor (PR), androgen receptor (AR), HER2, Ki67, and CK5/6 and fluorescence in situ hybridization for the HER2 gene were performed...
September 14, 2016: American Journal of Surgical Pathology
C Chiappa, F Rovera, S Rausei, S Del Ferraro, A Fachinetti, M Lavazza, V Marchionini, V Arlant, M L Tanda, E Piantanida, H Y Kim, A Anuwong, G Dionigi
INTRODUCTION: The aim of this study was to evaluate the association of breast cancer with thyroid diseases. Many authors have already studied the possible relationship between these two diseases, but the results are nowadays conflicting. MATERIALS AND METHODS: Our study examining 867 patients with breast cancer (862 women and 5 men, average age = 61 years old) of whom 141 also had thyroid disease evaluated the recurrence of thyroid diseases and their association with different types of breast cancer...
September 13, 2016: Journal of Endocrinological Investigation
Torsten O Nielsen, Maj-Britt Jensen, Samantha Burugu, Dongxia Gao, Charlotte L Tykjaer Jorgensen, Eva Balslev, Bent Ejlertsen
PURPOSE: Luminal A breast cancers have better prognosis than other molecular subtypes. Luminal A cancers may also be insensitive to adjuvant chemotherapy, although there is little high level evidence to confirm this concept. The primary hypothesis in this formal prospective-retrospective analysis was to assess interaction between subtype (Luminal A vs. other) and treatment (chemotherapy vs. not) for the primary endpoint (10-year invasive disease free survival) of a breast cancer trial randomizing women to adjuvant chemotherapy, analyzed in multivariate Cox proportional hazards models using the Wald interaction test...
September 6, 2016: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
Xiaojia Huang, Xing Li, Xinhua Xie, Feng Ye, Bo Chen, Cailu Song, Hailin Tang, Xiaoming Xie
OBJECTIVES: The purpose of this study was to investigate the potential correlation between lactate dehydrogenase A (LDHA) and AMP-activated protein kinase (AMPK) and their clinicopathologic significance in breast cancer. MATERIALS AND METHODS: Western blot and qRT-PCR were used to detect the expression levels of LDHA and AMPK in eight breast cancer lines and eight breast cancer tissues. In addition, LDHA and AMPK were detected by immunohistochemistry (IHC) using breast cancer tissue microarrays (TMAs) of 112 patients...
September 3, 2016: Breast: Official Journal of the European Society of Mastology
Yen-Ying Chen, Ling-Ming Tseng, Ching-Fen Yang, Pei-Ju Lien, Chih-Yi Hsu
BACKGROUND: Multigene assays are recommended for hormone receptor-positive invasive breast carcinoma to determine the risk of recurrence, but they are highly expensive. We investigated the prognostic values of immunohistochemistry (IHC)-based prognostic models as an alternative to multigene assays. METHODS: The risk categories estimated by the IHC-based prognostic models were correlated to those estimated by the multigene assays in 71 cases and the follow-up results in 642 consecutive cases of HER2- luminal-type early breast cancer...
August 29, 2016: Journal of the Chinese Medical Association: JCMA
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"